Davies et al_SEESAW EASD 2020 abstract_main outcomes.pdf (339.87 kB)
The SGLT2 inhibitor empagliflozin does not stimulate compensatory appetite responses in patients with excess adiposity and type 2 diabetes
conference contribution
posted on 2020-10-13, 09:43 authored by Melanie J Davies, Emma L Baldry, Danielle H Bodicoat, S Chatterjee, Charlotte L Edwardson, Laura J Gray, Kamlesh Khunti, Jack A Sargeant, David J Stensel, David R Webb, John P H Wilding, Scott A Willis, Tom Yates, James A KingConference abstract
Funding
Boehringer Ingelheim and supported in-kind by the NIHR Leicester BRC
History
Citation
Diabetologia 63, 1–485 (2020). https://doi.org/10.1007/s00125-020-05221-5Author affiliation
Diabetes Research Centre, College of Life SciencesSource
56th Annual Meeting of the European-Association-for-the-Study-of-Diabetes (EASD)Version
- AM (Accepted Manuscript)
